|
Patent landscape, scope, and claims: |
Scope, Claims, and US Patent Landscape for US 9,233,118 (Papulopustular Rosacea, Topical 1% Ivermectin Once Daily)
US Patent 9,233,118 claims a once-daily topical method for papulopustular rosacea using a pharmaceutical composition containing about 1% by weight ivermectin in a pharmaceutically acceptable carrier, with measured clinical effect framed as significant reduction in inflammatory lesion count. Dependent claims tighten timing (response “as early as 2 weeks”), add detailed formulation component lists, and position performance over a comparator regimen of twice-daily 0.75% metronidazole.
What exactly is claimed?
1. What is the independent claim scope?
The patent’s independent claim set is directed to methods of treatment, not to the composition per se, though it is composition-anchored in each method claim.
-
Claim 1 (independent):
Treat papulopustular rosacea in a subject in need thereof by topically administering once daily to the affected skin area a composition comprising:
- about 1% by weight ivermectin
- pharmaceutically acceptable carrier
- to obtain “a significant reduction in inflammatory lesion count.”
-
Claim 6 (independent, structurally parallel):
Treat inflammatory lesions of papulopustular rosacea by topically administering once daily the same about 1% ivermectin composition, to obtain “a significant reduction in inflammatory lesion count.”
Key scope attributes
- Route: topical to skin area affected by papulopustular rosacea.
- Frequency: once daily (not every-other-day).
- Drug loading: about 1% by weight ivermectin (allows small formulation/rounding variation around 1%).
- Outcome framing: “significant reduction in inflammatory lesion count” is the claimed therapeutic effect, used both for efficacy and as the enforceable method result.
2. What is the key dependent-claim scope expansion?
Dependent claims add (i) early onset of effect, (ii) explicit formulation ingredient classes, and (iii) superiority vs twice-daily metronidazole.
Timing
- Claim 2: significant reduction is observed as early as 2 weeks after initial administration.
- Claim 7: same timing concept for claim 6.
Formulation ingredient limitation (broad but specific lists)
Comparator superiority
- Claim 4 (for claim 1): once-daily ivermectin yields more reduction in inflammatory lesion count than twice-daily 0.75% metronidazole.
- Claim 5: once-daily ivermectin yields longer relapse-free time than twice-daily 0.75% metronidazole.
- Claims 10 and 11: same concepts attached to claim 8.
Claim-by-claim scope map (what is captured and what is not)
Claims 1 and 6: the core infringement hook
These claims capture any activity that matches all elements:
| Element |
Claim requirement |
Practical capture risk |
| Indication |
papulopustular rosacea |
Narrow disease phenotype (not rosacea generally) |
| Subject |
“subject in need thereof” |
Clinical need element typically satisfied by labeling/usage context |
| Act |
topical administration |
Cosmetics/skincare only is outside if not therapeutic method |
| Dosage form |
pharmaceutical composition |
Must be drug-like composition with carrier |
| Drug loading |
“about 1% by weight ivermectin” |
Design-around could use non-about levels (e.g., materially lower/higher) |
| Dosing frequency |
once daily |
Twice daily use does not fall into the literal “once daily” limitation |
| Therapeutic outcome |
significant reduction in inflammatory lesion count |
Must show clinical effect, typically supported by study design |
Claims 2 and 7: early effect window
- “As early as 2 weeks” adds a temporal performance requirement.
- If accused product shows efficacy but not by that timeline in clinical data, validity/enforcement may become a litigation axis (depending on how “significant reduction” is defined and demonstrated).
Claims 3 and 9: formulation ingredient scaffolding
This is not a claim to a fully specified recipe. It is a set-membership formulation limitation:
- The composition must “further comprise” selected ingredients from those groups.
- The groups are broad and include common topical excipient families (silicones, fatty alcohols/esters, nonionic emulsifiers, propylene glycol, phenoxyethanol, carbomer/xanthan/gums, water).
What this means for scope
- It is difficult to practice around without changing the formulation architecture or excluding key excipient categories.
- At the same time, the lists are “selected from” rather than “consists of,” which allows additional excipients beyond the listed groups while still satisfying the limitation (as drafted).
Claims 4-5 and 10-11: superiority over metronidazole
The claims explicitly set up comparative outcomes against:
- 0.75% metronidazole
- twice daily regimen
This makes the comparator important in both:
- enforcement (showing “more reduction” and “longer relapse-free time”), and
- validity (anticipation and obviousness tied to known metronidazole efficacy and dosing patterns, and to the clinical trial evidence used for “significant reduction” and relapse-free time).
What is the practical “infringement perimeter” for competitors?
Frequency limitation
- Once daily is central. A competitor using ivermectin topically twice daily may avoid literal infringement of these specific claims, though it could still face other claims in related families (not provided here) that do not require once-daily dosing.
Drug concentration
- The claim uses “about 1% by weight ivermectin.”
- Products at 0.5%, 0.75%, 0.9%, 1.2%, etc. could become fact-specific around whether the product meets “about” in practice.
- Non-ivermectin alternatives are outside scope.
Indication phenotype
- The method requires papulopustular rosacea.
- If a competitor labels for erythematotelangiectatic rosacea or mixed rosacea without papulopustular lesions as the target, the disease-connection element is a likely dispute.
Clinical effect language
- “Significant reduction in inflammatory lesion count” and “relapse-free time” anchor method claims in measurable endpoints.
- A competitor could attempt to argue lack of substantial evidence for those endpoints under the accused dosing conditions, but the claims themselves position those outcomes as part of the method.
Formulation limitation analysis (Claim 3 / Claim 9)
Excipient families enumerated
Claim 3 specifies the following compositional classes (not exhaustive, but required “further comprising” from the listed classes):
- Silicone components (oily phase)
- Dimethicone
- Cyclomethicone
- Ester emollients (oily phase)
- Isopropyl palmitate
- Isopropyl myristate
- Fatty substance set
- Cetyl alcohol
- Cetostearyl alcohol
- Stearyl alcohol
- Palmitostearic acid
- Stearic acid
- Self-emulsifiable wax
- Surfactant-emulsifier set
- Glyceryl/PEG100 stearate
- Sorbitan monostearate
- Sorbitan palmitate
- Steareth-20
- Steareth-2
- Steareth-21
- Ceteareth-20
- Solvents/propenetrating agents set
- Propylene glycol
- Oleyl alcohol
- Phenoxyethanol
- Glyceryl triacetate
- Gelling agents set (with explicit exclusion)
- Carbomers
- Cellulose gelling agents
- Xanthan gums
- Aluminum magnesium silicates, excluding the specific blend “aluminum magnesium silicate/titanium dioxide/silica”
- Guar gums
- Polyacrylamides
- Modified starches
- Water
Design-around strategies implied by the claim language
- Excluding key excipient classes (not simply swapping one emulsifier for another within the same enumerated set) would be the cleanest way to move outside Claims 3 and 9.
- If a competitor keeps the active and once-daily dosing but changes excipient families not in the listed sets, literal infringement of the dependent formulation-limited claims becomes less likely.
- However, Claims 1 and 6 do not incorporate these excipient lists. So formulation changes alone do not automatically avoid infringement if the base claim elements remain satisfied (once-daily ~1% ivermectin and therapeutic result).
Therapeutic outcome framing (what counts as “significant” and “relapse-free”)
The claims use:
- Inflammatory lesion count reduction
- Relapse-free time
These are typical clinical study endpoints. The comparator claims demand:
- better lesion reduction than twice daily 0.75% metronidazole
- longer relapse-free time than the same metronidazole regimen
Enforcement impact
- Litigation will likely focus on whether clinical evidence for the accused regimen shows:
- “significant reduction” at or before 2 weeks (for Claims 2/7)
- comparative superiority metrics relative to metronidazole for Claims 4/5/10/11
- If performance is derived from a specific trial, those trial parameters become material to claim interpretation.
US patent landscape: where US 9,233,118 sits relative to competitive vectors
Because the user provided only the claim text and not the full bibliographic record, the analysis below is limited to landscape logic tied to the claim scope elements (active, concentration, dosing frequency, indication, endpoints, and comparator). The landscape vectors that typically cluster around this kind of claim set are:
1. Ivermectin topical rosacea families
Competitors facing this patent are generally:
- other ivermectin topical products in rosacea with:
- ~1% ivermectin
- topical once daily
- papulopustular lesions as the target
- or reformulations that alter excipients but keep the same active concentration and dosing schedule.
2. Metronidazole topical performance-comparison families
Because the claims expressly recite metronidazole at 0.75% and twice daily, the comparative advantage language tends to appear in the evidentiary record and may be attacked via:
- known metronidazole efficacy profiles
- dosing regimen effects (once vs twice daily)
- differences in study design and endpoint definitions
3. Other topical agents
Other actives (e.g., azelaic acid, topical antibiotics) are outside the ivermectin method scope. The primary competitive overlap is on:
- the same indication (papulopustular rosacea)
- same endpoint framework (inflammatory lesion count, relapse-free time)
- topical dosing frequencies
Risk matrix by claim category
| Claim set |
Main limiter |
Strongest challenge vector |
Who is most exposed |
| Claims 1 and 6 |
once-daily topical “about 1%” ivermectin; papulopustular rosacea; significant lesion reduction |
dosing frequency, concentration “about” interpretation, and indication linkage to papulopustular lesions |
Any once-daily ivermectin ~1% product meeting therapeutic endpoint |
| Claims 2 and 7 |
early effect by 2 weeks |
whether clinical data show significant reduction by 2 weeks under that regimen |
Once-daily ivermectin products with slower onset profiles |
| Claims 3 and 9 |
includes specific excipient families |
excipient substitution outside enumerated sets; move away from required classes |
Formulation-level variants attempting to avoid specific excipient architecture |
| Claims 4-5 and 10-11 |
superiority vs twice-daily 0.75% metronidazole |
comparative evidence, study comparability, endpoint measurement, relapse-free definition |
Products seeking to claim similar efficacy in a manner not evidencing superiority |
Bottom-line scope conclusions
What is the patent “about,” legally?
- A method of treating papulopustular rosacea using a topical once-daily composition with about 1% ivermectin, where efficacy is defined by clinical endpoint inflammatory lesion count reduction, with optional dependent constraints on early onset, formulation excipient classes, and superiority over twice-daily 0.75% metronidazole.
What is the strongest enforceable core?
- Claims 1 and 6 are the strongest because they omit the detailed excipient list and the metronidazole comparison. They still require the “significant reduction” endpoint, but they preserve maximal formulation flexibility.
What are the weaker or more contestable elements?
- Claims 2 and 7 (2-week observation) and Claims 4-5 / 10-11 (comparative superiority, relapse-free time) are more evidence-dependent. They can be litigated using clinical trial design, statistical thresholds, endpoint definitions, and comparability.
Key Takeaways
- US 9,233,118 enforces a once-daily topical method for papulopustular rosacea using about 1% by weight ivermectin with claimed clinical effect tied to inflammatory lesion count reduction.
- Dependent claims add 2-week early response, specific excipient categories (silicones, fatty esters/alcohols, selected emulsifiers, propylene glycol/phenoxyethanol-type solvents, and enumerated gelling agents with a targeted exclusion), and superiority vs twice-daily 0.75% metronidazole including relapse-free time.
- From a competitive standpoint, avoiding literal scope is most directly addressed by changing at least one of three elements: once-daily dosing, “about 1%” ivermectin concentration, or the papulopustular lesion treatment context. Excipient changes only clearly reduce risk for the formulation-limited dependent claims, not for the base claims.
FAQs
1. Does US 9,233,118 claim an ivermectin composition, or only a method?
It claims a method of treatment. The composition is defined in the claim elements (about 1% ivermectin and pharmaceutically acceptable carrier, and in dependent claims, additional excipient classes).
2. What is the most critical limitation to avoid infringement?
The patent requires once-daily topical administration of a composition comprising about 1% by weight ivermectin for papulopustular rosacea.
3. Do the excipient lists apply to the independent claims?
No. The independent claims (1 and 6) do not recite the detailed excipient sets. The detailed excipient lists appear in dependent claims (3 and 9).
4. What does the metronidazole language do to the claim scope?
It narrows the dependent claims to situations where once-daily ivermectin produces more lesion reduction and longer relapse-free time than twice-daily 0.75% metronidazole.
5. Is “as early as 2 weeks” required for all claims?
No. The 2-week language is in dependent claims (2 and 7). The independent claims do not specify the time-to-response.
References
[1] US Patent 9,233,118, claims text provided by user (papulopustular rosacea; once-daily topical method; about 1% by weight ivermectin; inflammatory lesion count reduction; dependent excipient and metronidazole comparative limitations).
More… ↓
⤷ Start Trial
|
